Ocugen, Inc. (OCGN:NASDAQ) closed at $0.841 on October 14, 2026, down 4.99% on the day. The stock trades 69.1% below its 52-week high of $2.73 and 7.2% above its 52-week low of $0.785. Over the past year, it lost 45.7%. Ocugen, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -7.38% | -16.47% | -35.37% | -55.51% | -45.68% |
In 252 trading sessions since October 14, 2025, OCGN closed higher on 109 days (43%). Its best day was March 11, 2026 (+29.94%) and its worst was September 9, 2026 (-19.92%). The stock moved 10% or more in a single session 10 times.
Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).
Find more stocks like OCGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.